3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
175
Recurrence
32
Neoplasms, Plasma Cell
16
Lymphoma
11
Waldenstrom Macroglobulinemia
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Smoldering Multiple Myeloma
4
Leukemia
4
Small Cell Lung Carcinoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Plasma Cell
3
Hodgkin Disease
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Disease
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Salivary Gland Adenoma, Pleomorphic
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
carfilzomib
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled
NCT02204241
2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2
Completed
36 enrolled